Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin–bound paclitaxel in patients with advanced solid tumors

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|121|11|1817-1826

ISSN： 0008-543x

Source： CANCER, Vol.121, Iss.11, 2015-06, pp. : 1817-1826

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Interstitial Lung Disease Following Single-Agent Nanoparticle Albumin-Bound Paclitaxel Treatment in Patients with Advanced Non-Small Cell Lung Cancer

By  

Case Reports in Oncology, Vol. 10, Iss. 2, 2017-08 ,pp. : 683-688

Karger

Access to resources Recommend Favorite

Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid Tumors

By  

Oncology, Vol. 91, Iss. 5, 2016-09 ,pp. : 251-260

Karger

Access to resources Recommend Favorite

Nanoparticle albumin‐bound paclitaxel can be useful agent to advanced primary mucinous carcinoma of the skin

By  

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY & VENEREOLOGY, Vol. 29, Iss. 11, 2015-11 ,pp. : 2271-2273

John Wiley & Sons Inc

Access to resources Recommend Favorite

Nanoparticle albumin-bound paclitaxel: a novel Cremphor-EL®®-free formulation of paclitaxel

By Stinchcombe Thomas E  

Nanomedicine, Vol. 2, Iss. 4, 2007-08 ,pp. : 415-423

Future Medicine

Access to resources Recommend Favorite

Toxic erythema with eccrine squamous syringometaplasia induced by nanoparticle albumin‐bound paclitaxel

By  

THE JOURNAL OF DERMATOLOGY, Vol. 42, Iss. 11, 2015-11 ,pp. : 1134-1135

John Wiley & Sons Inc

Access to resources Recommend Favorite